c-erbB-2 (Her2-neu) is very important gene that is expressed in 30% of breast carcinoma. This test is performed now routinely in USA in all breast carcinoma cases. The significance of this gene in clinical practice is the following
Associated with high histologic grade-
(Associated with shortened disease free survival (early relapse–
The higher the level of c-erbB-2 , the worse is the prognosis–
CMF (cyclophosphomide/methotrexate/5-fluorouracil) has less effect on positive cases–
(Good Response to doxorubicin – containing regimens (CAF) (cyclophosphomide/ doxorubicin /5-fluorouracil–
(Taxol ( paclitaxel) can be influential in c-erbB-2 (Her2-neu–
Can be associated with positive or negative estrogen receptor studies–
More resistance to radiotherapy–
Herceptin ( a new drug : monoclonal anti- c-erbB-2) have a good effect on treatment of positive cases–
Now, this test can be performed in the First Medical Laboratories at a reduced cost. Results of the test will be available within few days of requesting the test
Our lab is determined to bring always what is new and clinically relevant to clinical practice in Jordan
Please call us for any further information
Dr. Hussam Abu-Farsakh
American boards of Anatomic, Clinical Pathology and Cytopathology